A research paper reporting a series of case studies of cancer patients, including a few brain tumour patients, has just been published. Dr Julian Kenyon of the Dove Clinic has been using a synthetic form of pharamaceutical grade cannabidiol (CBD) oil obtained from a UK drugs company called STI Pharmaceuticals and claims that this particular product is what made the difference, compared with other oils that can be bought over the internet.
The aim of the study was to assess the effects of this pharmaceutical-grade synthetic cannabidiol on a range of cancer patients. Dr Julian Kenyon collaborated with Dr Wai Liu and Angus Dalgleish at St George’s University of London to analyse the data routinely collected, as part of the treatment programme at the Dove Clinic, in 119 cancer patients over a four-year period. Clinical responses were seen in 92% of the 119 cases (which included a range of cancer types)